Gilead Science的新艾滋病毒预防药物Lenacapavir可在6月前获得批准,每年两次注射一次。 Gilead Sciences' new HIV prevention drug, lenacapavir, could be approved by June, offering twice-yearly injections.

如果到2025年6月19日获得林业发展局的批准,Gilead Science的新药物Lenacapavir可成为首种长效艾滋病毒注射预防药物,每年服用两次。 Gilead Sciences' new drug, lenacapavir, could become the first long-acting injectable HIV prevention drug, administered twice yearly, if it receives FDA approval by June 19, 2025. 该药物在临床试验中减少了96%的风险,被视为在预防艾滋病毒方面取得的重大进展。 The drug showed a 96% risk reduction in clinical trials and is seen as a significant advancement in HIV prevention. Gilead的股票在新闻上上涨了2%。 Gilead's stock rose 2% on the news.